Events6th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session C. General: Presentations of the event 6th International Electronic Conference on Medicinal Chemistry
Published date
06 Nov, 2020
Citation
Lucia Sessa, Anna Maria Nardiello, Jacopo Santoro, Stefano Piotto, Simona Concilio, Computational study to develop new bromodomain-containing protein 9 inhibitors, in Proceedings of 6th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2020, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2020-07450
Share
Email
Facebook
Twitter
LinkedIn

Computational study to develop new bromodomain-containing protein 9 inhibitors

image
image
image
1. Department of Pharmacy, University of Salerno, 84084 Fisciano (SA), Italy, Italy
2. Research Centre for Biomaterials BIONAM, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano (SA), Italy
3. Department of Pharmacy, University of Salerno, 84084 Fisciano (SA), Italy
Abstract

Bromodomain represents a large family of evolutionary protein modules that bind acetylated lysines. Bromodomain-containing protein 9 (BRD9) plays a role in chromatin remodeling and regulation of transcription. Because of its biological role, there is growing interest in this protein as a potential therapeutic target.

The main task of this work was to identify new potential inhibitors of BRD9 by using an evolution of the classic fragment-based methods. Starting from a crystallographic structure (PDB 5IGN), we built a hit molecule directly inside the active site of the protein. We designed a structure able to interact with the key residues in the binding site and with new unexplored sites. We selected several analogs to use as lead compounds by an extensive and automatic search of the scaffold structure on ZINC databases. We created a combinatorial library of potential inhibitors based on topological information directly in the binding site during a molecular dynamics simulation. We have selected the best inhibitor potential based on binding energy and residence time. Our approach could be tailored to several systems. The main strength of the approach is the speed of the analysis and the accuracy of the results.

Keywords
BDR9
drug design
fragment-based
Oral Presentation
Poster
Electronic_Conference_on_Medicinal_Chemistry_PPT_Sessa_Lucia. (1).pdf
Synthesis, characterization and cytotoxicity of Mn(II) and Cu(II) complexes with N-substituted glycine hydrazone
Viability of different tumor cell lines after treatment with complexes of oligoribonucleotides with D-mannitol